Group 1: Market Performance - The Hang Seng Healthcare Index (HSHCI) decreased by 0.18% as of July 10, 2025, with mixed performance among constituent stocks [3] - Major gainers included Giant Bio (02367) up 4.24%, Yaoshi Bang (09885) up 4.13%, and Dongyangguang Changjiang Pharmaceutical (01558) up 3.48% [3] - The Hang Seng Healthcare ETF (513060) fell by 0.17%, with a latest price of 0.58 yuan, but saw a 2.48% increase over the past week [3] Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) announced measures to optimize lifecycle regulation to support high-end medical device innovation, particularly benefiting the in vitro diagnostics (IVD) industry [4] - Policies include accelerated approvals and international registration facilitation, which will enhance the global competitiveness of IVD companies [4] - The document from NMPA is expected to directly benefit the IVD sector, with domestic biochemical diagnostics largely free from foreign constraints [4] Group 3: ETF Performance Metrics - The Hang Seng Healthcare ETF recorded a financing buy-in of 220 million yuan and a financing balance of 267 million yuan [5] - Over the past two years, the ETF's net value increased by 20.23%, with a maximum monthly return of 28.34% and an average monthly return of 6.82% [5] - As of July 4, 2025, the ETF's one-year Sharpe ratio was 2.07, indicating strong risk-adjusted returns [5] Group 4: Valuation and Tracking - The Hang Seng Healthcare ETF has a current price-to-earnings ratio (PE-TTM) of 27.84, which is below the historical average, indicating a low valuation compared to the past three years [6] - The ETF has the highest tracking accuracy among comparable funds, with a tracking error of 0.069% over the past year [5][6] - The ETF's management fee is 0.50%, and the custody fee is 0.15%, contributing to its overall cost structure [5]

甬江实验室 特聘研究员 苏瑞涛 将出席 2025（第四届）高分子3D打印材料高峰论坛 （7月18-20 日 | 浙江 · 杭州），并分享 "功能材料与器件的 3D 打印" 。 高精度3D打印技术（如双光子聚合、电流体动力喷印和计算轴向光刻）可制造特征尺寸低至 100纳 米 的复杂结构。 近年来，关于 3D打印微流控器件 的研究和进展越来越来。许多研究人员采用了3D打印技术作为制 造微流控芯片的技术手段，3D打印技术为微流控芯片制备的标准化和批量生产提供了广阔的前景。 由于3D打印具有快速反馈和3D几何图形的自由成型的能力，这为微流控芯片的生产提供了很好的支 撑，并带来微流控芯片的类型和尺寸等方面的创新。除此之外，在3D打印机精密控制、新材料开发 和高分辨率打印等方面改进可以制作更小更复杂的3D打印微流控系统，从而带来微流控芯片制造方 法的变革。 微流控芯片制造技术从半导体微纳制造技术衍生而来。微流控芯片具有 功耗低、自动化程度高、分 析速度快、样本量小、批量制造、多通道分析一体化 等优点，该技术可以大大提高实验效率，减少 材料消耗，节省时间和金钱成本。 近年，甬江实验室的 苏瑞涛研究员 在其综述中详细地介绍了 ...

Group 1 - The event "Science and Innovation Zhengzhou · Co-creating the Future" aims to build a collaborative innovation platform between government, enterprises, and research institutions to accelerate the transformation of scientific research achievements and support the high-quality development of private enterprises in Zhengzhou [1][2] - Eleven private enterprises visited the Harbin Institute of Technology Zhengzhou Research Institute to learn about technological breakthroughs in fields such as medical health, optoelectronics, and intelligent manufacturing [1] - The North Beijing University Zhengzhou Research Institute showcased key projects in new materials and mixed reality digital technology, highlighting the industrialization potential of these research outcomes [1][2] Group 2 - The Shangjie District is actively exploring the integration of technological and industrial innovation, establishing a mechanism for continuous enterprise-research institution collaboration to facilitate project incubation and policy support [2] - The Harbin Institute of Technology Zhengzhou Research Institute and North Beijing University Zhengzhou Research Institute are deeply integrated into the innovation-driven development strategy of Henan Province, providing strong support for regional industrial transformation [2] - The Harbin Institute of Technology Zhengzhou Research Institute has successfully incubated companies like Henan Carbon True Core Material Technology, promoting advanced technologies in superhard materials and extending the industrial chain [2] Group 3 - The Zhengzhou Science and Technology Bureau plans to continue organizing diverse enterprise-research institution matching activities to support the establishment of joint innovation centers and accelerate the industrialization of scientific research achievements [3]

分别在 2016 年、2018 年获得深圳市科创委技术攻关项目资助 市场与合作 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月18日， 美好医疗 发布了2024年年报。 # 财报数据 # 关于美好医疗 深圳市美好创亿医疗科技股份有限公司成立于 2010 年，总部位于深圳市龙岗区。公司主要产品包含一次性 使用无菌混合喷药装置、聚醚醚酮（PEEK）颅颌面固定板、一次性结扎夹等。还从事精密模具、自动化设 备、智能制造系统的设计、开发、生产及销售，以及医用植入金属材料、高分子材料、硅胶材料的制造等。 产品和技术 营业收入 ： 2024 年实现营业收入 15.94 亿 元，同比增长 19.19% 。 其中，医疗业务收入 13.43 亿 元，占比 84.23%，同比增长 24.53%；非医疗业务收入 2.51 亿元，占比 15.77%，同比下降 3.04%， 医疗业务是推动公司整体营收上升的主要动力。 净利润 ： 归属于上市公司股东的净利润为 3.64 亿 元，同比增长 16.11% ； 扣除非经常性损益后的净利 润为 3.5 亿元， ...